phs000280.v5.p1 Atherosclerosis Risk in Communities (ARIC) Cohort | Versions 1-5: passed embargo
| VDAS | 15678 | Longitudinal, Cohort | | |
phs000888.v1.p1 eMERGE Network Imputed GWAS for 41 phenotypes | Version 1: passed embargo
| VDAS | 55029 | Case-Control, Cohort | Links | 1000 Genomes
|
phs001584.v1.p1 eMERGE Network Phase III: HRC Imputed Array Data of 83,000+ Participants | Version 1: passed embargo
| VDAS | 83717 | Case-Control | | Nimblegen Custom SeqCap
|
phs000007.v30.p11 Framingham Cohort | Versions 1-30: passed embargo
| VDAS | 15154 | Longitudinal | | HuGeneFocused50K_Affy Mapping250K_Nsp Mapping250K_Sty Mapping50K_Hind240 Mapping50K_Xba240
|
phs001326.v1.p1 A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1, 1968 | Version 1: passed embargo
| VDAS | 748 | Longitudinal, Observational, Cross-Sectional | | |
phs001392.v1.p1 Natural History Study of SCID Disorders | Version 1: passed embargo
| VDAS | 30 | Longitudinal | | |
phs000228.v4.p1 HMP Core Microbiome Sampling Protocol A (HMP-A) | Versions 1-4: passed embargo
| VDAS | 300 | Population-Based Control Set | Links | 454 GS FLX Titanium 454 GS FLX Titanium
|
phs000090.v4.p1 GENEVA: The Atherosclerosis Risk in Communities (ARIC) Study | Versions 1-4: passed embargo
| VDAS | 12771 | Case-Control | | AFFY_6.0
|
phs000200.v12.p3 Women's Health Initiative | Versions 1-11: passed embargo Version 12:
| VDAS | 143213 | Partial Factorial Randomized, Double-Blind, Placebo-Controlled, Cohort, Longitudinal | Links | |
phs000353.v1.p1 GENEVA Study of Preterm Delivery (African-American) | Version 1: passed embargo
| VDAS | 3478 | Case-Control | Links | HumanOmni1-Quad_v1-0_B
|
phs000309.v3.p2 The CARDIA-GENEVA Study | Versions 1-3: passed embargo
| VDAS | 1926 | Longitudinal | Links | AFFY_6.0
|
phs001278.v1.p1 Longitudinal Study of the Porphyrias | Version 1: passed embargo
| VDAS | 198 | Longitudinal | Links | |
phs000592.v1.p1 Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias | Version 1: passed embargo
| VDAS | 341 | Longitudinal, Prospective | Links | |
phs001575.v1.p1 Assessment of Neurological Deterioration in Subjects with LINCL | Version 1: passed embargo
| VDAS | 42 | Longitudinal | | |
phs000424.v8.p2 Genotype-Tissue Expression (GTEx) | Versions 1-8: passed embargo
| VDAS | 980 | Tissue Expression, Reference Set | | HumanOmni5-Quad HumanOmni2.5 Infinium HumanExome BeadChip HiSeq 2000 HiSeq 2000 GeneChip Human Gene 1.0 ST Array HiSeq 2000 HiSeq X Ten
|
phs000096.v4.p1 HAPO Maternal Glycemia and Birthweight GEI Study | Versions 1-4: passed embargo
| VDAS | 9987 | Prospective, Observational, Cohort | Links | Human1M-Duov3_B Human610_Quadv1_B HumanOmni1-Quad_v1-0_B
|
phs000092.v1.p1 Study of Addiction: Genetics and Environment (SAGE) | Version 1: passed embargo
| VDAS | 4121 | Case-Control | Links | ILMN_Human-1
|
phs000594.v1.p1 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia | Version 1: passed embargo
| VDAS | 9 | Interventional, Clinical Trial | Links | |
phs000360.v3.p1 eMERGE Network Combined Dataset | Versions 1-3: passed embargo
| VDAS | 18663 | Case-Control | Links | Human660W-Quad_v1_A Human1M-Duov3_B
|
phs000605.v1.p1 Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial) | Version 1: passed embargo
| VDAS | 111 | Clinical Trial, Clinical Diagnostic Testing, Randomized Controlled Clinical Trial | Links | |